

The Phosphoinositide 3-Kinase Isoform PI3K β Regulates Osteoclast-Mediated Bone Resorption in Humans and Mice

Dávid Győri,¹ Dániel Csete,¹ Szilvia Benkő,² Suhasini Kulkarni,³ Péter Mandl,⁴ Csaba Dobó-Nagy,⁵ Bart Vanhaesebroeck,⁶ Len Stephens,³ Phillip T. Hawkins,³ and Attila Mócsai¹

Objective. While phosphoinositide 3-kinases (PI3Ks) are involved in various intracellular signal transduction processes, the specific functions of the

different PI3K isoforms are poorly understood. We have previously shown that the PI3K β isoform is required for arthritis development in the K/BxN serum-transfer model. Since osteoclasts play a critical role in pathologic bone loss during inflammatory arthritis and other diseases, we undertook this study to test the role of PI3K β in osteoclast development and function using a combined genetic and pharmacologic approach.

Methods. The role of PI3K β in primary human and murine osteoclast cultures was tested with the PI3K β -selective inhibitor TGX221 and by using PI3K β ^{-/-} mice. The trabecular bone architecture of PI3K β ^{-/-} mice was evaluated using micro-computed tomography and histomorphometric analyses.

Results. The expression of PI3K β was strongly and specifically up-regulated during *in vitro* osteoclast differentiation. *In vitro* development of large multinucleated osteoclasts from human or murine progenitors and their resorption capacity were strongly reduced by the PI3K β inhibitor TGX221 or by the genetic deficiency of PI3K β . This was likely due to defective cytoskeletal reorganization and vesicular trafficking, since PI3K β ^{-/-} mouse multinucleated cells failed to form actin rings and retained intracellular acidic vesicles and cathepsin K. In contrast, osteoclast-specific gene expression and the survival and apoptosis of osteoclasts were not affected. PI3K β ^{-/-} mice had significantly increased trabecular bone volume and showed

Supported by the Hungarian Scientific Research Fund (grant OTKA F-68782 to Dr. Benkő), the Ludwig Institute for Cancer Research (grant to Dr. Vanhaesebroeck), the Wellcome Trust (program grant WT085889MA to Drs. Stephens and Hawkins), the UK Biotechnology and Biological Sciences Research Council (grants BB/DO13593/1 and BBS/B/01979 to Drs. Stephens and Hawkins), the European Research Council (Starting Independent Investigator Award 206283 to Dr. Mócsai), the European Union Seventh Framework Programme (project TARKINAID; Cooperation Program grant 282095 to Dr. Mócsai), and the Lendület Programme of the Hungarian Academy of Sciences (grant LP2013-66/2013 to Dr. Mócsai). Dr. Győri's work was supported by an EMBO Short-Term Fellowship from the European Molecular Biology Organization. Dr. Benkő's work was supported by a Zoltán Magyary Postdoctoral Fellowship. Dr. Kulkarni's work was supported by a C. J. Martin Fellowship awarded by the National Heart Foundation (Australia) and the National Health and Medical Research Council (Australia). Dr. Mócsai was recipient of an International Senior Research Fellowship (087782) from the Wellcome Trust.

¹Dávid Győri, MD, Dániel Csete, MD, Attila Mócsai, MD, PhD: Semmelweis University School of Medicine, and MTA-SE "Lendület" Inflammation Physiology Research Group of the Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary; ²Szilvia Benkő, PhD: University of Debrecen, Debrecen, Hungary; ³Suhasini Kulkarni, PhD, Len Stephens, PhD, Phillip T. Hawkins, PhD: Babraham Institute, Cambridge, UK; ⁴Péter Mandl, MD, PhD: Medical University of Vienna, Vienna, Austria; ⁵Csaba Dobó-Nagy, DMD, PhD: Semmelweis University School of Dentistry, Budapest, Hungary; ⁶Bart Vanhaesebroeck, MSc, PhD, FmedSci: Queen Mary University of London, London, UK.

Dr. Vanhaesebroeck has received consulting fees, speaking fees, and/or honoraria from Karus Therapeutics and Intellikine/Millennium, the Takeda Oncology Company (less than \$10,000 each) and from Activiomics (more than \$10,000), owns stock or stock options in Activiomics, and has submitted patent applications for phosphoproteomics and new phosphoinositide 3-kinase drug targets. Drs. Stephens and Hawkins have received consulting fees, speaking fees, and/or honoraria from Karus Therapeutics and GlaxoSmithKline (less than \$10,000 each); Dr. Hawkins also owns stock in Karus Therapeutics.

Address correspondence to Attila Mócsai, MD, PhD, Department of Physiology, Semmelweis University School of Medicine, Tűzoltó utca 37-47, 1094 Budapest, Hungary. E-mail: mocsai.attila@med.semmelweis-univ.hu.

Submitted for publication October 8, 2013; accepted in revised form April 3, 2014.

abnormal osteoclast morphology with defective resorption pit formation.

Conclusion. PI3K β plays an important role in osteoclast development and function and is required for in vivo bone homeostasis.

Phosphoinositide 3-kinases (PI3Ks) comprise a diverse family of lipid kinases involved in nearly all cellular functions as well as various disease processes ranging from cancer to metabolic and inflammatory diseases (1–6). The best known mammalian PI3Ks are the class I PI3K family members PI3K α , PI3K β , PI3K γ , and PI3K δ (2,7). PI3K α , PI3K β , and PI3K δ mainly relay signals downstream from receptor or nonreceptor tyrosine kinases, whereas PI3K γ is primarily involved in signal transduction by the $\beta\gamma$ subunits of certain G protein-coupled receptors (2,7).

The functional role of PI3Ks had initially been addressed by using general PI3K inhibitors such as wortmannin or LY294002. However, more recent studies using genetic deletion approaches and the recent development of isoform-specific PI3K inhibitors have revealed highly specific functions of the different isoforms in certain biologic processes, promising novel therapeutic strategies for various disease states (2,4).

We previously demonstrated that PI3K β is required for arthritis development in the K/BxN serum-transfer model (8). Since that model mimics the myeloid cell-mediated effector phase of arthritis, PI3K β was most likely required in one (or more) myeloid lineage cell types.

Osteoclasts are highly specialized bone-resorbing cells of myeloid hematopoietic cell origin (9–11) and are responsible for basal bone resorption as well as pathologic bone loss during inflammatory arthritis, bone metastasis, and postmenopausal osteoporosis. Their role in inflammatory arthritis is indicated by reduced arthritis-induced local bone resorption upon genetic or pharmacologic blockade of osteoclasts, both in experimental mice (12–14) and in patients with rheumatoid arthritis (15).

Osteoclast development and function are directed by a number of extracellular cues including macrophage colony-stimulating factor (M-CSF), RANKL, β_3 integrin-mediated adhesive interactions, and immunoreceptor-like activation signals (9–11, 16,17). Wortmannin and LY294002 inhibit both the development and the resorptive activity of osteoclasts (18–21). However, the role of the different PI3K isoforms in osteoclast development and function is poorly understood.

These issues prompted us to analyze the role of PI3K β in primary in vitro osteoclast cultures and in in vivo bone homeostasis, using a combined genetic and pharmacologic approach. Our results indicate that PI3K β plays a major role in osteoclast development, osteoclast-mediated bone resorption, and in vivo bone homeostasis, likely due to its participation in the organization of the osteoclast cytoskeleton and the release of intracellular vesicles.

MATERIALS AND METHODS

Animals. *Pik3cb*^{tm1.1Bvan/tm1.1Bvan} (PI3K β ^{-/-}) mice carrying a homozygous deletion of exons 21–22 of *Pik3b*, the gene encoding the p110 β catalytic subunit of PI3K β , were described previously (22) and were maintained in heterozygous form on a mixed C57BL/6:129Sv genetic background (backcrossed to C57BL/6 for ~4 generations). Age- and sex-matched wild-type controls (mostly littermates) were obtained from the same colony. Transgenic mice ubiquitously expressing enhanced green fluorescent protein (EGFP)-tagged Lifeact (23) were provided by Dr. Michael Sixt (Institute of Science and Technology, Klosterneuburg, Austria) and were crossed with PI3K β ^{+/+} mice to obtain Lifeact-EGFP-expressing PI3K β ^{-/-} mice. For pharmacologic studies, C57BL/6 mice were purchased from Charles River.

Due to the limited availability of PI3K β ^{-/-} mice, bone marrow cells for most in vitro osteoclast and macrophage cultures were obtained from bone marrow chimeras generated by transplanting PI3K β ^{-/-} (and parallel wild-type control) mouse bone marrow cells to lethally irradiated recipients, as previously described (24,25). No differences have been observed between osteoclast cultures derived from intact mice and those derived from corresponding bone marrow chimeras of either genotype (data not shown).

Mice were kept in individually sterile ventilated cages (Tecniplast) in a conventional facility. All animal experiments were approved by the Semmelweis University Animal Experimentation Review Board.

In vitro culture and resorption assays. In vitro osteoclast cultures were performed essentially as previously described (26). Wild-type or PI3K β ^{-/-} mouse bone marrow cells were first cultured in the presence of 10 ng/ml mouse M-CSF (PeproTech) for 2 days. Nonadherent cells (referred to as myeloid progenitors) were then plated at 2×10^5 cells/cm² and cultured in the presence of 20 or 50 ng/ml recombinant mouse M-CSF and 20 or 50 ng/ml mouse RANKL (both from PeproTech) with media/cytokine changes every 2 days. Osteoclast morphology was tested 3 days later, using a commercial tartrate-resistant acid phosphatase (TRAP) staining kit (Sigma) and imaged using a Leica DMI6000B inverted microscope, and the number of osteoclasts (defined as TRAP-positive cells with ≥ 3 nuclei) was counted manually. The diameter of the cells was determined using ImageJ software (National Institutes of Health). For in vitro resorption assays, osteoclasts were cultured under similar conditions for 11 days on an artificial hydroxyapatite layer (BD BioCoat Osteologic slides) or on bovine cortical bone slices (Immunodiagnostic

Systems), then processed according to the manufacturer's instructions, followed by imaging and determination of the resorbed area using ImageJ software.

For osteoblast–osteoclast coculture experiments, calvariae of euthanized neonatal wild-type mice were digested by 0.1% collagenase and 0.25% trypsin–EDTA (both from Sigma) in 5 consecutive rounds. The cells isolated during the last 3 rounds were plated at 10^5 cells/well in 96-well plates and cultured for 2 days in the presence of 10 nM 1,25-dihydroxyvitamin D₃ and 10 nM dexamethasone (both from Sigma). Wild-type or PI3K $\beta^{-/-}$ mouse bone marrow cells were then seeded onto the osteoblasts at 5×10^4 cells/well and cultured for 10 days with media changes every 2 days. TRAP expression was then determined as described above. Wild-type and PI3K $\beta^{-/-}$ mouse macrophages were generated by culturing myeloid progenitors in the presence of 50 ng/ml M-CSF without the addition of RANKL.

Human osteoclasts were differentiated from peripheral blood mononuclear cells (PBMCs) from healthy volunteers. PBMCs were obtained by dextran sedimentation and centrifugation through Ficoll-Paque (GE Healthcare) as previously described (27). Mononuclear cells were washed and plated at 2×10^5 cells/cm² to 24-well tissue culture plates or BD BioCoat Osteologic slides and cultured in the presence of 20 or 50 ng/ml recombinant human M-CSF and 20 or 50 ng/ml human RANKL (both from PeproTech) for 14 days with media/cytokine changes every 2 days. TRAP staining and resorption assays were performed as described above. Experiments on human cells were approved by the Semmelweis University Regional and Institutional Committee of Science and Research Ethics.

For inhibitor studies, wortmannin (Sigma) and TGX221 (Cayman Chemical) were added either concomitantly with the initial RANKL treatment or 3 days later and then replaced, with media changes every 2 days. Vehicle control samples were treated with 0.1% DMSO or ethanol.

Detection of apoptosis. For survival analysis, pre-osteoclasts obtained by culturing mouse myeloid progenitors for 2 days in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL were suspended by 0.25% trypsin–EDTA (Sigma) and either analyzed immediately or cultured for an additional 12 or 18 hours in α -minimum essential medium in the absence of serum/cytokines. Cells were stained with phycoerythrin-conjugated annexin V and 7-aminoactinomycin D (7-AAD) (Apoptosis Detection Kit; BD PharMingen) according to the manufacturer's instructions and analyzed on a BD FACSCalibur flow cytometer.

For the TUNEL reaction, osteoclast cultures were stained with a Roche In Situ Cell Death Detection Kit, AP, according to the manufacturer's instructions. The number of TUNEL-positive cells was counted manually.

Fluorescence microscopy. For F-actin staining, mouse myeloid progenitors were cultured for the indicated time periods in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL with or without the indicated inhibitors, fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 (Sigma), and stained with 1:400 Alexa Fluor 488–conjugated phalloidin (Invitrogen) and 1:1,000 DAPI (Invitrogen). After several washes, fluorescence was observed using a Leica DMI6000B inverted microscope.

For live imaging of osteoclast development, myeloid progenitors obtained from Lifeact–EGFP–transgenic wild-

type or PI3K $\beta^{-/-}$ mice were cultured for the indicated time period in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL with or without the indicated inhibitors, and imaged using an Essen BioScience IncuCyte Zoom imaging system inside a tissue culture incubator or a Nikon BioStation IM-Q imaging system (Auro-Science Hungary). Videos were generated using IncuCyte Zoom Controller 2013A or Nikon BioStation IM software. For acidic vesicle staining, mouse myeloid progenitors cultured for 3 days in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL were incubated for 20 minutes with LysoTracker Red (Invitrogen) according to the manufacturer's instructions, then fixed, stained with DAPI, and imaged as described above.

Analysis of gene expression. To test gene expression changes, mouse myeloid progenitors were cultured for 0–3 days in the presence of 50 ng/ml M-CSF with or without 50 ng/ml RANKL, followed by RNA extraction and reverse transcription as previously described (26,28). Quantitative reverse transcription–polymerase chain reaction was then performed using TaqMan assays for the mouse genes *Pik3ca* (Mm00435673_m1), *Pik3cb* (Mm00659576_m1), *Pik3cg* (Mm00445038_m1), and *Pik3cd* (Mm00435674_m1) and the osteoclast-specific genes *Acp5*, *Ctsk*, *Itgb3*, *Calcr*, *Nfatc1*, and *Tm7sf4* as previously described (26). Transcript levels relative to GAPDH were calculated using the comparative C_t method (26).

Cathepsin K secretion. Mouse myeloid progenitors were cultured for 3 days in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL and then stimulated with 50 ng/ml phorbol myristate acetate (Sigma) for 10 minutes. The supernatants were collected, and the proteins were precipitated with acetone. Whole-cell lysates were obtained using Triton X-100–based lysis buffer (29). Samples were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis and immunoblotted with mouse monoclonal antibodies against cathepsin K (E-7; Santa Cruz Biotechnology) with secondary reagents from GE Healthcare.

Micro-computed tomography (micro-CT) analysis. Trabecular bone structure and mineralization were tested by micro-CT analysis of the distal metaphysis of the femurs of age- and sex-matched wild-type and PI3K $\beta^{-/-}$ mice essentially as described previously (26). Micro-CT sections were acquired using a SkyScan 1172 micro-CT apparatus with an isometric voxel size of 4.5 μ m, followed by reconstitution of a horizontal section 250 sections proximal to the distal growth plate and reconstitution of a 3-dimensional axial cylinder 700 μ m in diameter expanding from 150 to 450 sections proximal to the distal growth plate, as well as calculation of quantitative micro-CT parameters using SkyScan NRecon and CT-Analyser software (both from SkyScan) as described previously (26).

Histomorphometric analysis. Histomorphometry studies were performed on the distal metaphysis of the femurs of age-matched wild-type and PI3K $\beta^{-/-}$ male mice at ages 8–10 weeks. Bones were fixed, decalcified in 14% EDTA, embedded in paraffin, and sectioned and stained with TRAP, toluidine blue, and hematoxylin and eosin. Histomorphometric analysis was performed using a Zeiss Axioskop 2 microscope equipped with a video camera and an OsteoMeasure system (OsteoMetrics) according to international standards as described previously (30).




Figure 1. Expression of phosphoinositide 3-kinase β (PI3K β) during in vitro osteoclast development. Gene expression was analyzed in wild-type mouse myeloid precursors cultured for the indicated time periods in the presence of 50 ng/ml macrophage colony-stimulating factor with 50 ng/ml RANKL (osteoclasts) (A) or without RANKL (macrophages) (B). The expression of the *Pik3ca*, *Pik3cb*, *Pik3cg*, and *Pik3cd* (encoding the catalytic subunits of PI3K α , PI3K β , PI3K γ , and PI3K δ , respectively) was determined by quantitative reverse transcription–polymerase chain reaction. Bars show the mean \pm SEM from 3 independent experiments.

Statistical analysis. All experiments were performed ≥ 3 times (or on ≥ 3 individual mice), with comparable results. Statistical analysis was performed using Student's unpaired 2-sample *t*-test.

RESULTS

PI3K β expression during osteoclast development. We first tested the expression of the various PI3K isoforms during in vitro differentiation of mouse progenitors in the presence of 50 ng/ml M-CSF with (osteoclasts) or without (macrophages) 50 ng/ml RANKL. As shown in Figure 1A, the expression of PI3K β but not of the other PI3K isoforms was dramatically up-regulated during osteoclast differentiation. In contrast, no substantial changes were seen in parallel macrophage cultures (Figure 1B). Therefore, consistent with a recent report (31), PI3K β was dramatically and specifically up-regulated during osteoclast development.

Inhibition of PI3K β blocks osteoclast development and function in vitro. To assess the functional role of PI3K β in osteoclasts, we next tested the effect of the PI3K β inhibitor TGX221 on in vitro-generated osteoclasts. As shown in Figure 2A, the nonselective PI3K inhibitor wortmannin completely blocked development of osteoclasts (large multinucleated TRAP-positive cells) generated by culturing mouse myeloid progenitors in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL. TGX221 also dose-dependently inhibited osteoclast development by $\sim 90\%$ at a concentration of 50 nM, a dose thought to specifically inhibit PI3K β (8,32,33) (Figure 2) (further information is available at semmelweis.hu/elettan/en/?p=664).

We also tested the effect of TGX221 on the resorptive activity of osteoclasts. As shown in Figure 2B, 50 nM wortmannin abrogated the resorption of an

artificial hydroxyapatite surface by murine osteoclast cultures generated using 50 ng/ml M-CSF and 50 ng/ml RANKL. TGX221 at 50 nM also nearly completely blocked the resorptive activity of osteoclasts under such conditions (Figure 2B).

We next tested the effect of TGX221 on human osteoclasts differentiated from PBMCs in the presence of 50 ng/ml human M-CSF and 50 ng/ml human RANKL. Both wortmannin and TGX221 strongly reduced the number of osteoclasts, with 50 nM TGX221 causing $\sim 70\%$ inhibition (Figure 2C) (further information is available at semmelweis.hu/elettan/en/?p=664). In addition, 50 nM wortmannin or 50 nM TGX221 dramatically inhibited the in vitro resorptive capacity of human osteoclasts on an artificial hydroxyapatite layer (Figure 2D). Results similar to those described above were obtained when the concentration of M-CSF and RANKL was reduced to 20 ng/ml (further information is available at semmelweis.hu/elettan/en/?p=664). Taken together, these findings show that PI3K β likely plays an important role in the in vitro development and resorptive function of both human and mouse osteoclasts.

In vivo bone homeostasis in PI3K β ^{-/-} mice. To test the role of PI3K β in osteoclast biology and bone homeostasis using a genetic approach, we turned to the analysis of PI3K β ^{-/-} mice carrying a targeted deletion within the catalytic domain of PI3K β (22). We first analyzed trabecular bone structure using micro-CT analysis of the distal metaphysis of the femurs at ages 8–10 weeks. As shown in Figure 3A, significantly more trabeculae were seen in PI3K β ^{-/-} mice, both in representative single micro-CT slices and in 3-dimensional reconstruction of an axial cylinder. Quantification of the entire trabecular area (Figure 3B) revealed significantly increased percent bone volume/total volume (BV/TV)




Figure 2. Pharmacologic inhibition of phosphoinositide 3-kinase β (PI3K β) blocks development and function of murine and human osteoclasts. Shown are representative images and quantification of tartrate-resistant acid phosphatase (TRAP)-stained cell cultures of (A and C), and in vitro resorption pit formation by (B and D) wild-type mouse bone marrow-derived osteoclasts (A and B) and human blood mononuclear cell-derived osteoclasts (C and D) cultured for 3 days (A), 11 days (B), or 14 days (C and D) in the presence of 50 ng/ml macrophage colony-stimulating factor, 50 ng/ml RANKL, and the indicated concentrations of PI3K inhibitors or 0.1% vehicle. Resorption pits appear as lighter areas. Osteoclasts are defined as TRAP-positive cells with ≥ 3 nuclei. In vitro resorption is defined as the percentage of resorbed area. Bars show the mean \pm SEM from 3 independent experiments. Images are representative of 8–20 (A), 4–9 (B), or 3–4 (C and D) independent experiments.

in PI3K $\beta^{-/-}$ mice in both females ($P = 0.000029$; $n = 8$) and males ($P = 0.000084$; $n = 8$), which was primarily due to increased trabecular number rather than increased thickness of the individual trabeculae. The increased BV:TV ratio was seen across all age groups tested (further information is available at semmelweis.hu/elettan/en/?p=664).

We also performed histologic and histomorphometric analysis of the trabecular bone of the distal femurs. Trabecular density was increased in PI3K $\beta^{-/-}$

mice (Figure 3C); the quantitative BV:TV ratio ($P = 0.0059$; $n = 5$) and trabecular number, but not trabecular thickness, were also increased in PI3K $\beta^{-/-}$ mice (Figure 3D).

We next analyzed osteoclasts visible in the TRAP-stained histologic sections. There was a moderate but not statistically significant ($P = 0.44$; $n = 5$) reduction in the average number of osteoclasts per bone perimeter in PI3K $\beta^{-/-}$ mice (Figure 3D). Further analysis revealed that osteoclasts in PI3K $\beta^{-/-}$ mouse




Figure 3. Phosphoinositide 3-kinase β (PI3K β) is required for in vivo bone homeostasis in mice. **A**, Representative single micro-computed tomography (micro-CT) cross-sections (left) and 3-dimensional reconstitution of an axial cylinder (right) of the trabecular area of the distal femoral metaphysis of 9-week-old wild-type (WT) and PI3K $\beta^{-/-}$ female mice. **B**, Quantitative micro-CT analysis of the trabecular bone architecture of WT and PI3K $\beta^{-/-}$ female and male mice ages 8–10 weeks. **C**, Representative images of histomorphometric analysis of the trabecular area of WT and PI3K $\beta^{-/-}$ male mice at age 8 weeks. Original magnification $\times 10$. **Insets** show enlarged view of tartrate-resistant acid phosphatase-stained sections with osteoclasts (**arrows**) and resorption pits (**arrowheads**). **D**, Histomorphometric analysis of the trabecular bone architecture and the number of osteoclasts (OC), the length of attachment of osteoclasts to the trabecular bone surface (OC bone contact length), and the depth of the resorption pits. Data were obtained from 8 (**A** and **B**) or 5 (**C** and **D**) mice per genotype. Bars show the mean \pm SEM. * = $P < 0.05$; ** = $P < 0.01$; *** = $P < 0.002$; **** = $P < 0.0004$. BV/TV = bone volume/total volume; NS = not significant.

sections were more rounded (Figure 3C, inset) with significantly shorter bone contact length ($P = 0.030$; $n = 30$ osteoclasts) (Figure 3D). In addition, the depth of resorption pits was dramatically reduced in PI3K $\beta^{-/-}$ mouse sections ($P = 0.0089$; $n = 30$ osteoclasts) (Figures 3C [inset] and D). Taken together, these results indicate that PI3K $\beta^{-/-}$ mice have increased trabecular bone volume, likely caused by moderately reduced numbers and abnormal morphology/function of osteoclasts.

PI3K β deficiency impairs osteoclast development and function in vitro. Next, we tested the effect of the PI3K $\beta^{-/-}$ mutation on in vitro osteoclast develop-

ment and function. As shown in Figure 4A, PI3K β deficiency led to reduced numbers of osteoclasts generated in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL ($P = 0.0015$; $n = 5$), and the average diameter of those cells was even more dramatically reduced ($P = 0.00083$; $n = 5$). Similar results were obtained when the concentration of M-CSF and RANKL was reduced to 20 ng/ml (further information is available at semmelweis.hu/elettan/en/?p=664). Fluorescence labeling of DNA (Figure 4A) also revealed significantly decreased numbers of nuclei per osteoclast ($P = 0.018$; $n = 6$).

We also tested osteoclast differentiation in




Figure 4. Genetic deficiency of PI3K β leads to defective osteoclast development and function. Shown are representative images and quantification of tartrate-resistant acid phosphatase-stained cell cultures of (A and B) and in vitro resorption pit formation on artificial hydroxyapatite (C) or on bovine bone slices (D) by WT and PI3K $\beta^{-/-}$ mouse bone marrow-derived osteoclasts cultured for 3 days (A), 10 days (B), or 11 days (C and D) in the presence of 50 ng/ml macrophage colony-stimulating factor and 50 ng/ml RANKL (A, C, and D) or with WT mouse calvarial osteoblasts (B). Bars show the mean \pm SEM from 5–6 independent experiments. Images are representative of 8–10 (A), 3–4 (B), or 4–5 (C and D) independent experiments. * = $P < 0.05$; *** = $P < 0.002$; **** = $P < 0.0004$. See Figure 3 for definitions.

osteoblast–osteoclast cocultures. We observed a moderate but not statistically significant ($P = 0.12$; $n = 5$) reduction of the number of osteoclasts differentiated from PI3K $\beta^{-/-}$ mouse bone marrow cells. However, the diameter of osteoclasts was dramatically reduced in PI3K $\beta^{-/-}$ mouse cell cultures ($P = 0.00012$; $n = 5$).

We next tested the resorptive activity of PI3K $\beta^{-/-}$ mouse cell cultures. PI3K β deficiency strongly reduced the resorptive capacity of in vitro osteoclast cultures in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL, both on an artificial hydroxyapatite surface ($P = 0.00042$; $n = 5$) (Figure 4C) and on bovine bone slices ($P = 6.2 \times 10^{-6}$; $n = 5$) (Figure 4D). Results similar to those described above were obtained when the concentration of M-CSF and RANKL was reduced to 20 ng/ml

(further information is available at semmelweis.hu/elettan/en/?p=664). Taken together, these findings demonstrate that genetic deficiency of PI3K β impairs in vitro development and resorptive function of osteoclasts.

PI3K β is not required for osteoclast-specific gene expression. To better understand the role of PI3K β in osteoclasts, we next tested the expression of osteoclast-specific genes during differentiation of murine myeloid progenitors in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL (osteoclasts) or M-CSF alone (macrophages). As shown in Figure 5A, the expression of *Acp5* (encoding TRAP), *Ctsk* (encoding cathepsin K), *Igfb3* (encoding integrin β_3 chain), *Nfatc1* (encoding NF-ATc1), *Calcr* (encoding calcitonin receptor), and *Tm7sf4* (encoding dendritic cell-specific trans-




Figure 5. PI3K β is not required for up-regulation of osteoclast-specific gene expression and survival of osteoclasts. **A**, Gene expression in WT and PI3K $\beta^{-/-}$ mouse bone marrow-derived cells cultured for the indicated time periods in the presence of 50 ng/ml macrophage colony-stimulating factor (M-CSF) with 50 ng/ml RANKL (osteoclasts; OC) or without RANKL (macrophages; MΦ). The expression of *Acp5*, *Ctsc*, *Itgb3*, *Nfatc1*, *Calcr*, and *Tm7sf4* (encoding tartrate-resistant acid phosphatase, cathepsin K, integrin β_3 chain, NF-ATc1, calcitonin receptor, and dendritic cell-specific transmembrane protein, respectively) was determined by quantitative reverse transcription-polymerase chain reaction. **B** and **C**, Representative flow cytometric profiles (**B**) and quantification (**C**) of the binding of phycoerythrin (PE)-conjugated annexin V (apoptosis marker) and 7-aminoactinomycin D (7-AAD) (necrosis marker) to WT and PI3K $\beta^{-/-}$ mouse preosteoclasts (generated by culturing myeloid precursors in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL for 2 days) before (0 hours) or after serum and cytokine starvation for 12 or 18 hours. Surviving cells are defined as negative for both PE-conjugated annexin V and 7-AAD staining. **D**, Analysis of the number of TUNEL-positive cells in WT and PI3K $\beta^{-/-}$ mouse bone marrow-derived osteoclast cultures. Data are from 3 (**A**) or 5-6 (**B-D**) independent experiments. Bars show the mean \pm SEM. See Figure 3 for other definitions.

membrane protein) was strongly increased during osteoclast differentiation but not during macrophage differentiation. PI3K β deficiency did not affect the expression of any of those genes (Figure 5A), indicating that PI3K β is not required for osteoclast-specific gene expression.

Normal survival and apoptosis of PI3K $\beta^{-/-}$ mouse osteoclast-lineage cells. To test the role of PI3K β deficiency in survival and apoptosis of osteoclast-lineage cells, preosteoclasts were generated by culturing myeloid progenitors in 50 ng/ml M-CSF and 50 ng/ml RANKL for 2 days, followed by withdrawal of serum and cytokines for 12 or 18 hours. As shown in Figures 5B and C, ~90% of the preosteoclasts before serum/cytokine withdrawal (0-hour samples in Figure 5B) were negative for the apoptosis marker annexin V and the necrosis marker 7-AAD, whereas serum/cytokine withdrawal triggered

apoptosis and then necrosis of the cells. No difference in any of those processes was observed between cultures of cells from wild-type and PI3K $\beta^{-/-}$ mice (Figures 5B and C).

We also tested apoptosis in regular osteoclast cultures by in situ TUNEL staining. As shown in Figure 5D, ~12% of cells were TUNEL positive in cultures of osteoclasts from both wild-type and PI3K $\beta^{-/-}$ mice. Taken together, the observations suggest that PI3K β deficiency does not affect survival, apoptosis, or necrosis of osteoclast-lineage cells.

PI3K β is required for actin ring formation. We next tested whether PI3K β is required for the formation of the osteoclast actin ring, which is likely involved in sealing the resorption pit. A continuous F-actin ring was observed at the periphery of most wild-type mouse osteoclasts in the presence of 50 ng/ml M-CSF and




Figure 6. PI3K β is required for actin ring formation and cathepsin K secretion by murine osteoclasts. **A** and **C** (left), Representative fluorescence images (**A**) and quantification (**C** [left]) of WT and PI3K $\beta^{-/-}$ mouse myeloid precursors cultured in the presence of 50 ng/ml macrophage colony-stimulating factor and 50 ng/ml RANKL for 3 days and then stained with Alexa Fluor 488-conjugated phalloidin and DAPI. **Arrows** in **A** show the actin ring. Values in **C** (left) are the percentage of osteoclasts with closed actin rings at the cell periphery. **B** and **C** (right), Representative fluorescence images (**B**) and quantification (**C** [right]) of WT and PI3K $\beta^{-/-}$ mouse myeloid precursors cultured under conditions similar to those described in **A** and then stained with LysoTracker Red and DAPI. An acidic vesicle is marked with an **arrow** in **B**. Values in **C** (right) are the number of acidic vesicles. Boxed areas at left in **A** and **B** are shown at higher magnification at right. **D**, Immunoblot (left) and densitometric quantification (right) of cathepsin K (Ctsk) in the supernatant or whole-cell lysates (WCL) of WT and PI3K $\beta^{-/-}$ mouse bone marrow cells cultured as described in **A**. Fluorescence images are representative of 4–6 independent experiments; immunoblot is representative of 4 independent experiments. Bars show the mean \pm SEM from 3–6 independent experiments. ** = $P < 0.01$; **** = $P < 0.0004$. See Figure 3 for other definitions.

50 ng/ml RANKL (Figures 6A and C). In contrast, even multinucleated cells in PI3K $\beta^{-/-}$ mouse osteoclast cultures rarely showed a clear F-actin ring, and F-actin was instead accumulated in the cytoplasm and distinct patches at the cell periphery ($P = 7.8 \times 10^{-8}$; $n = 6$).

We also assessed temporal changes of actin

polymerization using transgenic mice expressing EGFP-tagged Lifeact, a short peptide specifically binding to fibrillar actin. As shown in Supplementary Videos 1 and 2 (available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.38660/abstract>) (further information is available at

semmelweis.hu/elettan/en/?p=664), osteoclasts derived from Lifeact–EGFP–expressing wild-type mouse progenitor cells began to form continuous F-actin rings ~2 days after addition of RANKL, and these remained visible until the osteoclasts succumbed to apoptosis. In contrast, osteoclast-like cells from Lifeact–EGFP–transgenic PI3K $\beta^{-/-}$ mice failed to form actin rings and instead showed patchy/dispersed Lifeact distribution. Taken together, these findings indicate that PI3K β plays an important role in the formation of the osteoclast actin ring.

PI3K $\beta^{-/-}$ mouse osteoclasts retain acidic vesicles and fail to release cathepsin K. During bone resorption, osteoclasts deliver and exocytose lysosome-related, cathepsin K–containing acidic vesicles to the ruffled border (34). Since prior studies proposed a role for PI3K activity in this process (31,35), we tested the distribution of acidic vesicles in PI3K $\beta^{-/-}$ mouse cell cultures in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL. While wild-type mouse osteoclasts contained very few small acidic vesicles, PI3K $\beta^{-/-}$ mouse cells were fully packed with such vesicles, suggesting that they cannot be discharged and therefore are retained in PI3K $\beta^{-/-}$ mouse cells ($P = 0.0021$; $n = 5$) (Figures 6B and C).

Exocytosis of the matrix-degrading enzyme cathepsin K plays an important role in osteoclast-mediated bone resorption. As shown in Figure 6D, the PI3K $\beta^{-/-}$ mutation substantially reduced the amount of cathepsin K in the supernatant of osteoclast cultures ($P = 0.0064$; $n = 3$). Taken together, these results show that the absence of PI3K β leads to defective actin ring formation, accumulation of acidic vesicles, and impaired release of cathepsin K into the extracellular space.

Inhibition of PI3K β after osteoclast formation blocks resorption and actin ring maintenance. The above results suggested that PI3K β not only is involved in osteoclast development but also plays important functional roles in mature osteoclasts. To test that possibility, we investigated the effect of PI3K β inhibition after the formation of mature osteoclasts. As shown at semmelweis.hu/elettan/en/?p=664, adding 50 nM TGX221 to osteoclast cultures starting from 3 days after the initial RANKL treatment strongly inhibited resorption of an artificial hydroxyapatite layer ($P = 0.0093$; $n = 3$). As shown at semmelweis.hu/elettan/en/?p=664, treatment of osteoclasts with 50 nM TGX221 for 6 hours starting 3 days after the initial RANKL treatment (when mature osteoclasts with complete actin rings have already been formed) led to the disappearance of actin rings ($P = 2.4 \times 10^{-4}$; $n = 3$). Kinetic analysis of the

effect of TGX221 using Lifeact–EGFP–expressing cells revealed that the actin rings began to resolve immediately after TGX221 treatment and became highly fragmented within a few hours (further information is available at semmelweis.hu/elettan/en/?p=664) (see Supplementary Videos 3 and 4, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.38660/abstract>). Taken together, these observations suggest that inhibition of PI3K β blocks the resorptive function and actin ring maintenance of in vitro osteoclast cultures even if performed several days after initial RANKL treatment.

DISCUSSION

Recent studies revealed highly specific functions of the various PI3K isoforms, triggering development of isoform-specific PI3K inhibitors for therapeutic purposes (2,36). Although prior studies suggested a role for PI3K activity in osteoclast development and bone resorption (18–21), little is known about the specific PI3K isoform(s) participating in those responses. Our initial gene expression studies (Figure 1) suggested a functional role for PI3K β in osteoclasts, which was tested using a detailed genetic and pharmacologic approach. Those studies revealed a critical role for PI3K β in in vitro development and resorbing function of primary human and mouse osteoclasts (Figures 2 and 4) and in vivo bone homeostasis in experimental mice (Figure 3).

Reduced osteoclast-mediated bone resorption may be due to failure of osteoclast development or defective resorptive function of mature osteoclasts. While PI3K β appears to play a role in osteoclast development under certain conditions (Figures 2A and C, Figures 4A and B), the most dramatic in vitro effects of PI3K β inactivation were observed when testing resorptive function or cellular parameters related to bone resorption (Figures 2, 4, and 6). Osteoclasts from PI3K $\beta^{-/-}$ mice also showed reduced bone contact length and resorption pit depth in vivo (Figure 3D). Furthermore, addition of TGX221 to cultures with mature osteoclasts inhibited bone resorption and led to rapid disassembly of preexisting actin rings (further information is available at semmelweis.hu/elettan/en/?p=664). Those results suggest that the most critical role for PI3K β is to mediate the resorptive function of mature osteoclasts.

We recently reported the analysis of phospholipase C γ 2–deficient (PLC γ 2 $^{-/-}$) mouse osteoclast cultures and bone morphology (26). It is interesting to note that while PI3K $\beta^{-/-}$ and PLC γ 2 $^{-/-}$ mice had similar

increases in trabecular bone mass, PLC γ 2^{-/-} mouse cells showed a much more robust in vitro osteoclast developmental defect than PI3K β ^{-/-} mouse cells. Those results again suggest that the primary defect in PI3K β ^{-/-} mice lies in the bone-resorbing function of osteoclasts.

The exact position of PI3K β in osteoclast signal transduction pathways is at present poorly understood. Osteoclast development and function are triggered through a large number of extracellular signals (9–11,16,17). Our initial experiments suggested that PI3K β is required for phosphorylation of Akt in response to M-CSF treatment (data not shown). However, a more detailed analysis of signaling by the various cell surface receptors and downstream signaling intermediates, as well as high-resolution imaging of phosphatidylinositol 3,4,5-trisphosphate generation in osteoclast cultures, would be needed to define the exact position of PI3K β in intracellular signaling of osteoclasts. Nevertheless, our findings indicate that PI3K β activation participates in reorganization of the actin cytoskeleton and release of cathepsin K-containing acidic vesicles (Figure 6) but not in gene expression changes or survival/apoptosis of the cells (Figure 5).

The results of prior studies using nonspecific PI3K inhibitors suggested a role for PI3Ks in osteoclast development and function (18–21). A few reported attempts to narrow the list of PI3K isoform(s) involved failed to reveal a major role for any of the specific PI3K isoforms, showed contradictory results, and were even inconsistent with a role for PI3K β (31,37,38). Our substantially more detailed experiments firmly identify PI3K β as a critical and likely predominant PI3K isoform involved in osteoclast development and function.

There is substantial interest in the pharmaceutical industry in the development of isoform-specific PI3K inhibitors for the treatment of various human diseases (1,3–5). Based on its role in platelet activation (32,39–43), PI3K β has been proposed to be a suitable target for the treatment of thrombotic diseases (44). Based on the results presented here, PI3K β may also be a suitable therapeutic target in diseases characterized by excessive osteoclast-mediated bone resorption such as rheumatoid arthritis, osteoporosis, or cancer-induced focal bone loss.

ACKNOWLEDGMENTS

We thank Edina Simon, Anna Tóth, and László Gölle for expert technical assistance; Michael Sixt for the Lifeact-EGFP-transgenic mice; Essen BioScience for the IncuCyte

Zoom system; Auro-Science Hungary for the Nikon BioStation IM-Q system; Bence Szabó for micro-CT scanning; Birgit Niederreiter for slide preparation for histomorphometry; and Norbert Gyöngyösi for help with statistical analysis.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Mócsai had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Gyóri, Kulkarni, Stephens, Hawkins, Mócsai.

Acquisition of data. Gyóri, Csete, Benkó, Dobó-Nagy.

Analysis and interpretation of data. Gyóri, Csete, Benkó, Kulkarni, Mandl, Dobó-Nagy, Vanhaesebroeck, Stephens, Hawkins, Mócsai.

REFERENCES

1. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. *Nat Rev Mol Cell Biol* 2012;13:195–203.
2. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. *Nat Rev Mol Cell Biol* 2010;11:329–41.
3. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer* 2009;9:550–62.
4. Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, et al. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. *Curr Med Chem* 2011;18:2686–714.
5. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. *Nat Rev Clin Oncol* 2013;10:143–53.
6. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. *Annu Rev Immunol* 2013;31:675–704.
7. Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through class I PI3Ks in mammalian cells. *Biochem Soc Trans* 2006;34:647–62.
8. Kulkarni S, Sitaru C, Jakus Z, Anderson KE, Damoulakis G, Davidson K, et al. PI3K β plays a critical role in neutrophil activation by immune complexes. *Sci Signal* 2011;4:ra23.
9. Teitelbaum SL. Bone resorption by osteoclasts. *Science* 2000;289:1504–8.
10. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature* 2003;423:337–42.
11. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. *Nat Rev Immunol* 2007;7:292–304.
12. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF- α -mediated joint destruction. *J Clin Invest* 2002;110:1419–27.
13. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, et al. Tumor necrosis factor α -mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. *Arthritis Rheum* 2002;46:785–92.
14. Herrak P, Gortz B, Hayer S, Redlich K, Reiter E, Gasser J, et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. *Arthritis Rheum* 2004;50:2327–37.
15. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al, on behalf of the Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-

- controlled, phase II clinical trial. *Arthritis Rheum* 2008;58:1299–309.
16. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. *Nature* 2004;428:758–63.
 17. Mocsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, Spusta SC, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor γ -chain (FcR γ) regulate development of functional osteoclasts through the Syk tyrosine kinase. *Proc Natl Acad Sci U S A* 2004;101:6158–63.
 18. Hall TJ, Jeker H, Schaubelin M. Wortmannin, a potent inhibitor of phosphatidylinositol 3-kinase, inhibits osteoclastic bone resorption in vitro. *Calcif Tissue Int* 1995;56:336–8.
 19. Nakamura I, Takahashi N, Sasaki T, Tanaka S, Udagawa N, Murakami H, et al. Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption. *FEBS Lett* 1995;361:79–84.
 20. Sato M, Bryant HU, Dodge JA, Davis H, Matter WF, Vlahos CJ. Effects of wortmannin analogs on bone in vitro and in vivo. *J Pharmacol Exp Ther* 1996;277:543–50.
 21. Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH, et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. *Bone* 2002;30:71–7.
 22. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, et al. The p110 β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110 γ . *Proc Natl Acad Sci U S A* 2008;105:8292–7.
 23. Riedl J, Flynn KC, Raducanu A, Gartner F, Beck G, Bosl M, et al. Lifeact mice for studying F-actin dynamics. *Nat Methods* 2010;7:168–9.
 24. Mocsai A, Zhou M, Meng F, Tybulewicz VL, Lowell CA. Syk is required for integrin signaling in neutrophils. *Immunity* 2002;16:547–58.
 25. Jakus Z, Simon E, Balazs B, Mocsai A. Genetic deficiency of Syk protects mice from autoantibody-induced arthritis. *Arthritis Rheum* 2010;62:1899–910.
 26. Kertesz Z, Gyori D, Kormendi S, Fekete T, Kis-Toth K, Jakus Z, et al. Phospholipase C γ 2 is required for basal but not oestrogen deficiency-induced bone resorption. *Eur J Clin Invest* 2012;42:49–60.
 27. Mocsai A, Jakus Z, Vantus T, Berton G, Lowell CA, Ligeti E. Kinase pathways in chemoattractant-induced degranulation of neutrophils: the role of p38 mitogen-activated protein kinase activated by Src family kinases. *J Immunol* 2000;164:4321–31.
 28. Benko S, Magalhaes JG, Philpott DJ, Girardin SE. NLR5 limits the activation of inflammatory pathways. *J Immunol* 2010;185:1681–91.
 29. Mocsai A, Banfi B, Kapus A, Farkas G, Geiszt M, Buday L, et al. Differential effects of tyrosine kinase inhibitors and an inhibitor of the mitogen-activated protein kinase cascade on degranulation and superoxide production of human neutrophil granulocytes. *Biochem Pharmacol* 1997;54:781–9.
 30. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res* 1987;2:595–610.
 31. Shinohara M, Nakamura M, Masuda H, Hirose J, Kadono Y, Iwasawa M, et al. Class IA phosphatidylinositol 3-kinase regulates osteoclastic bone resorption through protein kinase B-mediated vesicle transport. *J Bone Miner Res* 2012;27:2464–75.
 32. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, et al. PI 3-kinase p110 β : a new target for antithrombotic therapy. *Nat Med* 2005;11:507–14.
 33. Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, Okkenhaug K, et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. *Blood* 2005;106:1432–40.
 34. Coxon FP, Taylor A. Vesicular trafficking in osteoclasts. *Semin Cell Dev Biol* 2008;19:424–33.
 35. Nakamura I, Sasaki T, Tanaka S, Takahashi N, Jimi E, Kurokawa T, et al. Phosphatidylinositol-3 kinase is involved in ruffled border formation in osteoclasts. *J Cell Physiol* 1997;172:230–9.
 36. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. *Nat Rev Drug Discov* 2009;8:627–44.
 37. Grey A, Chaussade C, Empson V, Lin JM, Watson M, O'Sullivan S, et al. Evidence for a role for the p110- α isoform of PI3K in skeletal function. *Biochem Biophys Res Commun* 2010;391:564–9.
 38. Kang H, Chang W, Hurley M, Vignery A, Wu D. Important roles of PI3K γ in osteoclastogenesis and bone homeostasis. *Proc Natl Acad Sci U S A* 2010;107:12901–6.
 39. Canobbio I, Stefanini L, Cipolla L, Ciruolo E, Gruppi C, Balduini C, et al. Genetic evidence for a predominant role of PI3K β catalytic activity in ITAM- and integrin-mediated signaling in platelets. *Blood* 2009;114:2193–6.
 40. Kim S, Mangin P, Dangelmaier C, Lillian R, Jackson SP, Daniel JL, et al. Role of phosphoinositide 3-kinase β in glycoprotein VI-mediated Akt activation in platelets. *J Biol Chem* 2009;284:33763–72.
 41. Garcia A, Kim S, Bhavaraju K, Schoenwaelder SM, Kunapuli SP. Role of phosphoinositide 3-kinase β in platelet aggregation and thromboxane A $_2$ generation mediated by G $_i$ signalling pathways. *Biochem J* 2010;429:369–77.
 42. Martin V, Guillermet-Guibert J, Chicanne G, Cabou C, Jandrot-Perrus M, Plantavid M, et al. Deletion of the p110 β isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. *Blood* 2010;115:2008–13.
 43. Gratacap MP, Guillermet-Guibert J, Martin V, Chicanne G, Tronchere H, Gaits-Iacovoni F, et al. Regulation and roles of PI3K β , a major actor in platelet signaling and functions. *Adv Enzyme Regul* 2011;51:106–16.
 44. Nylander S, Kull B, Bjorkman JA, Ulvinge JC, Oakes N, Emanuelsson BM, et al. Human target validation of phosphoinositide 3-kinase (PI3K) β : effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K β inhibitor. *J Thromb Haemost* 2012;10:2127–36.